The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 24, 2015

Filed:

Oct. 29, 2010
Applicants:

Stephan Schann, Illkirch, FR;

Stanislas Mayer, Eschau, FR;

Christophe Morice, Widensolen, FR;

Bruno Giethlen, Altorf, FR;

Inventors:

Stephan Schann, Illkirch, FR;

Stanislas Mayer, Eschau, FR;

Christophe Morice, Widensolen, FR;

Bruno Giethlen, Altorf, FR;

Assignee:

Prestwick Chemical, Inc., Illkirch Graffenstaden, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/58 (2006.01); A01N 43/60 (2006.01); A61K 31/50 (2006.01); A61K 31/495 (2006.01); A01N 43/90 (2006.01); A61K 31/519 (2006.01); A01N 43/42 (2006.01); A61K 31/44 (2006.01); C07D 487/00 (2006.01); C07D 231/46 (2006.01); C07D 471/00 (2006.01); C07D 513/02 (2006.01); C07D 515/02 (2006.01); C07D 311/68 (2006.01); C07D 405/04 (2006.01); C07D 405/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 495/04 (2006.01); C07D 513/04 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 311/68 (2013.01); C07D 405/04 (2013.01); C07D 405/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01);
Abstract

The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGluR4.


Find Patent Forward Citations

Loading…